Springfield, Ma., USA - December 11, 2014, Springfield, Ma., USA - Massachusetts Mutual Life Insurance Company announced that it has elected Isabella D. Goren, Mark T. Bertolini and Jeffrey M. Leiden to its board of directors.
Article continues below
Ms. Goren is a former CFO of American Airlines, Inc. and AMR Corporation, a position she held from 2010-2013. She became a member of the Executive Committee in 2006, with her appointment as American’s Senior Vice President, Customer Relationship Marketing.
Ms. Goren joined the company in 1986 as a Financial Analyst, and held roles of progressively greater responsibility with the company, including management positions in Human Resources and Revenue Management, Director of Investor Relations, Vice President of Asia/Pacific operations and President of AMR Services, among others. She began her career in 1983 as a Chemical Engineer for DuPont.
Ms. Goren currently serves on the Board of Directors of both Gap Inc. and LyondellBasell Industries N.V., and is a Member of the Executive Board of Southern Methodist University’s School of Engineering.
She graduated with a Bachelor of Science in Chemical Engineering from the University of Texas, and earned her Master of Business Administration from Southern Methodist University. Ms. Goren’s appointment is effective December 9, 2014.
Mr. Bertolini has held several executive leadership roles with Aetna since joining the company in 2003 as Senior Vice President, Specialty Products. He was named President in 2007, President and CEO in 2010, and assumed his current role in 2011. From 1999-2003, he served in several leadership roles with Cigna Healthcare, Inc., and, prior to that, was for five years Executive Vice President with NYLCare Health Plans Inc.
Mr. Bertolini began his career in 1985 as Director of Business Development for SelectCare, Inc. He currently serves on Aetna’s Board of Directors, and is affiliated with several nonprofit entities.
Mr. Bertolini holds a Bachelor of Science in Business Administration from Wayne State University, and earned his Master of Business Administration from Cornell University. Mr. Bertolini’s appointment is effective February 10, 2015.
Dr. Leiden is currently Chairman, President and CEO of Vertex Pharmaceuticals Incorporated, a position he has held since 2012.
Prior to Vertex, from 2006-2012, Dr. Leiden was with Clarus Ventures, most recently as a Managing Director. From 2000-2006 he served as President and COO of Abbott Laboratories, Inc. where he was responsible for running the company’s Pharmaceutical Products Division.
Dr. Leiden has also held various leadership roles within the academic and medical communities, including positions with the Harvard University School of Public Health and the Harvard Medical School, the University of Chicago Hospitals & Health Systems, Pritzker School of Medicine, the University of Michigan Medical School and Brigham and Women’s Hospital.
He currently serves on the Boards of Vertex Pharmaceuticals, Quest Diagnostics and Brigham and Women’s Hospital. He formerly served on a number of corporate boards, including Abbott Laboratories, Millennium Pharmaceuticals, Inc., Shire PLC, TAP Pharmaceutical Products, Inc., TyRx Pharma, Inc., and Catabasis Pharmaceuticals. ■